Kronos Bio Announces Merger with Concentra Biosciences

The latest update is out from Kronos Bio ( (KRON) ).

On May 1, 2025, Kronos Bio announced a merger agreement with Concentra Biosciences, where Concentra will acquire Kronos Bio for $0.57 per share in cash plus a contingent value right (CVR). The merger, deemed beneficial by Kronos Bio’s Board of Directors, is expected to close mid-2025, subject to certain conditions including a tender offer for Kronos Bio’s outstanding shares and the availability of $40 million in net cash. The transaction aims to provide value to shareholders through potential proceeds from product dispositions and cost savings, with implications for Kronos Bio’s operational focus and shareholder returns.

Spark’s Take on KRON Stock

According to Spark, TipRanks’ AI Analyst, KRON is a Neutral.

Kronos Bio’s overall stock score is driven by significant revenue growth countered by ongoing profitability challenges and a weak valuation due to a negative P/E ratio. Technical indicators suggest a neutral stance, while a recent lease termination agreement positively impacts financial operations. Overall, these factors lead to a slightly below-average score.

To see Spark’s full report on KRON stock, click here.

More about Kronos Bio

Kronos Bio is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics aimed at addressing deregulated transcription, a characteristic of cancer and autoimmune diseases. The company operates a research facility in Cambridge, Massachusetts.

YTD Price Performance: -8.04%

Average Trading Volume: 151,932

Technical Sentiment Signal: Buy

Current Market Cap: $54.43M

For an in-depth examination of KRON stock, go to TipRanks’ Stock Analysis page.